Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Invasive Aspergillosis in Patients Treated With Ibrutinib

13 Feb 2020

Abstract excerpt

The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL) yielding unprecedented progression-free and overall survival rates in most CLL populations.1 Based on these data, ibrutinib has been widely approved for treatment of CLL and evaluated in various other B-cell malignancies leading to the approval in Waldenström's macroglobulinaemia (WM) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Immunodeficiency and Autoimmune Disorders
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32309779
DOI: 10.1097/hs9.0000000000000309

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Invasive Aspergillosis in Patients Treated With IbrutinibPMID 32309779Read ↗

Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosisSemantic proximity Read ↗

Skin Lesions in Patients Treated with BTK InhibitorsSemantic proximity Read ↗

Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.Semantic proximity Read ↗

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.Semantic proximity Read ↗

Ibrutinib in previously treated Waldenström's macroglobulinemia.Semantic proximity Read ↗

Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungus Aspergillus fumigatusSemantic proximity Read ↗

ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells.Semantic proximity Read ↗

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.Semantic proximity Read ↗

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.Semantic proximity Read ↗

A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.